DK1235589T3 - Præparater der omfatter neisseria meningitidis-antigener fra serogruppe B og C samt et yderligere antigen - Google Patents

Præparater der omfatter neisseria meningitidis-antigener fra serogruppe B og C samt et yderligere antigen

Info

Publication number
DK1235589T3
DK1235589T3 DK00981554T DK00981554T DK1235589T3 DK 1235589 T3 DK1235589 T3 DK 1235589T3 DK 00981554 T DK00981554 T DK 00981554T DK 00981554 T DK00981554 T DK 00981554T DK 1235589 T3 DK1235589 T3 DK 1235589T3
Authority
DK
Denmark
Prior art keywords
serogroup
compositions
well
neisseria meningitidis
additional antigen
Prior art date
Application number
DK00981554T
Other languages
Danish (da)
English (en)
Inventor
Marzia Monica Giuliani
Mariagrazia Pizza
Rino Rappuoli
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of DK1235589T3 publication Critical patent/DK1235589T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/116Polyvalent bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00981554T 1999-11-29 2000-11-29 Præparater der omfatter neisseria meningitidis-antigener fra serogruppe B og C samt et yderligere antigen DK1235589T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9928196.6A GB9928196D0 (en) 1999-11-29 1999-11-29 Combinations of B, C and other antigens
PCT/IB2000/001940 WO2001037863A2 (en) 1999-11-29 2000-11-29 Compositions comprising neisseria meningitidis antigens from serogroups b and c as well as a further antigen

Publications (1)

Publication Number Publication Date
DK1235589T3 true DK1235589T3 (da) 2009-06-22

Family

ID=10865363

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00981554T DK1235589T3 (da) 1999-11-29 2000-11-29 Præparater der omfatter neisseria meningitidis-antigener fra serogruppe B og C samt et yderligere antigen

Country Status (18)

Country Link
US (1) US9636393B2 (ja)
EP (3) EP1235589B1 (ja)
JP (5) JP5670003B2 (ja)
CN (4) CN101549154B (ja)
AT (1) ATE427756T1 (ja)
AU (2) AU784375B2 (ja)
BR (1) BR0015958A (ja)
CA (2) CA2392880C (ja)
CY (1) CY1109202T1 (ja)
DE (1) DE60041981D1 (ja)
DK (1) DK1235589T3 (ja)
ES (1) ES2322753T3 (ja)
GB (1) GB9928196D0 (ja)
MX (1) MXPA02005322A (ja)
NZ (2) NZ519608A (ja)
PT (1) PT1235589E (ja)
RU (2) RU2508122C2 (ja)
WO (1) WO2001037863A2 (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
DE69529219T2 (de) * 1994-07-01 2003-11-06 Chiron Corp Helicobacter proteine und impstoffe
ES2283012T3 (es) * 1996-01-04 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Bacterioferritina de helicobacter pylori.
WO1998012332A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
JP4812942B2 (ja) * 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル CGモチーフを含むオリゴヌクレオチドを用いるNeisseria抗原殺菌活性の増強
BRPI0112928B1 (pt) 2000-07-27 2017-08-29 Children's Hospital & Research Center At Oakland A composition comprising preparations comprising outer membrane vesicles (OMV), microvesicles (MV) or both MVO and MV
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
DK2248822T3 (en) 2001-07-27 2017-02-13 Glaxosmithkline Biologicals Sa MENINGOCOKKER ADHESIONS
JP2005506322A (ja) * 2001-08-31 2005-03-03 カイロン ソチエタ ア レスポンサビリタ リミタータ Helicobacterpyloriワクチン接種
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CN102319427A (zh) * 2003-01-30 2012-01-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
RU2378010C2 (ru) * 2003-10-02 2010-01-10 Новартис Вэксинес Энд Дайэгностикс С.Р.Л. Жидкие вакцины для множественных серогрупп менингококков
CU23236A1 (es) * 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0409750D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Integration of meningococcal conjugate vaccination
EP2433647A3 (en) 2005-01-27 2012-06-06 Children's Hospital & Research Center at Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CN101590225B (zh) * 2009-06-19 2012-02-15 长春长生生物科技股份有限公司 百白破、A+C群脑膜炎球菌-b型流感嗜血杆菌结合疫苗
WO2011110655A2 (en) * 2010-03-11 2011-09-15 Glaxosmithkline Biologicals S.A. Vaccine
BR112013004236A2 (pt) 2010-08-23 2016-07-12 Wyeth Llc formulações estáveis de antígenos de neisseria meningitidis rlp2086
ES2728282T3 (es) 2010-09-10 2019-10-23 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
KR101784644B1 (ko) 2012-03-09 2017-10-11 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX2015002717A (es) * 2012-09-06 2015-05-15 Novartis Ag Vacunas combinadas con meningococo del serogrupo b y toxoides de difteria/tetanos/tosferina.
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
KR20180099912A (ko) 2013-09-08 2018-09-05 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
CN107001450A (zh) * 2014-11-18 2017-08-01 巴斯德研究所 特异于脑膜炎奈瑟球菌的血清群x的多克隆抗体及其在诊断中的用途
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
JP6764021B2 (ja) 2016-09-02 2020-09-30 サノフィ パスツール インコーポレイテッド ナイセリア・メニンギティディスのワクチン
KR20220011796A (ko) 2017-01-31 2022-01-28 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
EP0273116A3 (en) 1986-10-09 1990-05-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Gonococcal and meningococcal polypeptides, vaccines and diagnostics
EP0449958B9 (en) 1988-12-19 2003-05-28 American Cyanamid Company Meningococcal class 1 outer-membrane protein vaccine
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
ATE121947T1 (de) * 1989-12-14 1995-05-15 Ca Nat Research Council Verbessertes meningokokkale polysaccharidkonjugatvakzin.
IE912559A1 (en) 1990-07-19 1992-01-29 Merck & Co Inc The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
EP0575553B1 (en) 1991-03-14 1998-12-16 Imclone Systems, Inc. Recombinant hybrid porin epitopes
DE122010000016I1 (de) 1992-05-23 2010-07-08 Glaxosmithkline Biolog Sa Kombinierte Impfstoffe, die Hepatitis-B-Oberflächen antigen und andere Antigene enthalten
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
EP0624376B1 (en) 1993-05-13 2000-03-15 American Cyanamid Company Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci
US5439808A (en) 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
ATE173634T1 (de) 1994-04-20 1998-12-15 Us Army Impfstoff gegen gram-negative bakterielle infektionen
FR2720408B1 (fr) 1994-05-31 1996-08-14 Pasteur Merieux Serums Vacc Fragments Tbp2 de Neisseria meningitidis.
IL117483A (en) * 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
CA2215162A1 (en) * 1995-03-23 1996-09-26 Cantab Pharmaceuticals Research Limited Vectors for gene delivery
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
DE69612198T3 (de) 1995-06-23 2011-08-18 Smithkline Beecham Biologicals S.A. Eine Impfstoffzusammensetzung, bestehend aus einem Haemophilus influenzae B Polysaccharid Antigen-Konjugat adsorbiert an Aluminiumphosphat
FR2739624B1 (fr) 1995-10-10 1997-12-05 Pasteur Merieux Serums Vacc Nouvelle sous-unite tbp2 de neisseria meningitidis
KR19990082265A (ko) * 1996-02-01 1999-11-25 다니엘 제이. 압둔-나비 효모중에서 b군 나이세리아 멘인기티디스 외막(mb3)단백질을 발현시키는 방법 및 백신
US6558677B2 (en) 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
WO1998058670A1 (en) 1997-06-24 1998-12-30 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
NZ502437A (en) 1997-07-17 2001-11-30 Baxter Healthcare Sa Immunogenic conjugates comprising H. influenzae type b (Hib) polysaccharide-recombinant refolded meningococcal outer membrane protein (rPorB) conjugate
JP4472866B2 (ja) * 1997-11-06 2010-06-02 カイロン ソチエタ ア レスポンサビリタ リミタータ ナイセリア抗原
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
ES2333071T5 (es) 1998-01-14 2015-08-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos de Neisseria meningitidis
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
ES2294629T3 (es) 1998-05-01 2008-04-01 Novartis Vaccines And Diagnostics, Inc. Antigenos de neisseria y composiciones.
GB9810276D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
EP1741443B1 (en) 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
EP2796148A3 (en) 1998-05-29 2015-02-25 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
MXPA01003557A (es) 1998-10-09 2004-04-05 Chiron Corp Secuencias genomicas de neisseria y metodos para su uso.
AU780308B2 (en) 1999-04-30 2005-03-17 J. Craig Venter Institute, Inc. Neisseria genomic sequences and methods of their use
ES2397918T3 (es) 1999-04-30 2013-03-12 Novartis Vaccines And Diagnostics S.R.L. Antígenos Neisseriales conservados
PT2270172E (pt) 1999-05-19 2016-03-31 Glaxosmithkline Biologicals Sa Composições de neisseria de combinação
EP2275551B1 (en) 1999-10-29 2015-04-08 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigenic peptides
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
BR0107679A (pt) 2000-01-17 2004-07-06 Chiron Spa Vacina de vesìcula de membrana externa (omv) compreendendo proteìnas de membrana externa do grupo sérico b de neisseria meningitidis
AU2818101A (en) 2000-01-25 2001-08-07 University Of Queensland, The proteins comprising conserved regions of neisseria meningitidis surface antigen NhhA
EP1790660B1 (en) 2000-02-28 2012-06-20 Novartis Vaccines and Diagnostics S.r.l. Heterologous expression of neisserial proteins
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
BRPI0112928B1 (pt) 2000-07-27 2017-08-29 Children's Hospital & Research Center At Oakland A composition comprising preparations comprising outer membrane vesicles (OMV), microvesicles (MV) or both MVO and MV
YU66103A (sh) 2001-01-23 2006-05-25 Aventis Pasteur Vakcina multivalentnog konjugata meningokokalnog polisaharid-proteina
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
CA2452720C (en) 2001-07-26 2012-04-17 Chiron S.R.L. Vaccines comprising aluminium adjuvants and histidine
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
DK2248822T3 (en) 2001-07-27 2017-02-13 Glaxosmithkline Biologicals Sa MENINGOCOKKER ADHESIONS
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
JP4740738B2 (ja) 2002-08-02 2011-08-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CN1809380B (zh) 2002-10-11 2010-05-12 启龙有限公司 广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
AU2003288558A1 (en) 2002-12-16 2004-07-09 Nasjonalt Folkehelseinstitutt Meningococcal vaccine based on outer membrane proteins porb2 and pora
CN102319427A (zh) 2003-01-30 2012-01-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
CA2524860C (en) 2003-05-07 2016-09-13 Aventis Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
RU2378010C2 (ru) 2003-10-02 2010-01-10 Новартис Вэксинес Энд Дайэгностикс С.Р.Л. Жидкие вакцины для множественных серогрупп менингококков
EP1706481A2 (en) 2003-12-23 2006-10-04 GlaxoSmithKline Biologicals S.A. Vaccine
GB0409748D0 (en) 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
EP2433647A3 (en) 2005-01-27 2012-06-06 Children's Hospital & Research Center at Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2009262893B2 (en) 2008-05-30 2015-05-21 The U.S.A., as represented by The Secretary of the Army, on behalf of Walter Reed Army Institute Of Research Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
GB0816284D0 (en) 2008-09-05 2008-10-15 Nat Biolog Standards Board Vaccine
WO2012031271A1 (en) 2010-09-04 2012-03-08 Novartis Ag Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição

Also Published As

Publication number Publication date
AU1878501A (en) 2001-06-04
EP1902726A3 (en) 2012-04-04
WO2001037863A3 (en) 2001-12-27
CA2392880C (en) 2012-03-06
CA2762106A1 (en) 2001-05-31
JP2017178971A (ja) 2017-10-05
ATE427756T1 (de) 2009-04-15
GB9928196D0 (en) 2000-01-26
EP1235589B1 (en) 2009-04-08
AU2010200336B2 (en) 2013-07-04
EP2289599A2 (en) 2011-03-02
NZ519608A (en) 2003-11-28
AU2010200336A1 (en) 2010-02-18
CA2392880A1 (en) 2001-05-31
JP2003514868A (ja) 2003-04-22
CN101549154B (zh) 2012-10-24
RU2508122C2 (ru) 2014-02-27
ES2322753T3 (es) 2009-06-26
RU2002117307A (ru) 2004-02-27
CN1433322A (zh) 2003-07-30
PT1235589E (pt) 2009-06-24
CA2762106C (en) 2015-09-01
JP2016041752A (ja) 2016-03-31
WO2001037863A2 (en) 2001-05-31
JP5670003B2 (ja) 2015-02-18
CN101822830A (zh) 2010-09-08
CN101549154A (zh) 2009-10-07
CN1507916A (zh) 2004-06-30
NZ529213A (en) 2005-03-24
DE60041981D1 (de) 2009-05-20
US9636393B2 (en) 2017-05-02
EP1902726A2 (en) 2008-03-26
AU784375B2 (en) 2006-03-23
BR0015958A (pt) 2003-02-25
CN100551441C (zh) 2009-10-21
RU2361609C2 (ru) 2009-07-20
CN101822830B (zh) 2016-06-01
JP2011093942A (ja) 2011-05-12
JP2014028863A (ja) 2014-02-13
RU2009105117A (ru) 2010-08-27
CY1109202T1 (el) 2014-07-02
US20050074450A1 (en) 2005-04-07
EP1235589A2 (en) 2002-09-04
EP2289599A3 (en) 2012-04-04
MXPA02005322A (es) 2002-12-06

Similar Documents

Publication Publication Date Title
DK1235589T3 (da) Præparater der omfatter neisseria meningitidis-antigener fra serogruppe B og C samt et yderligere antigen
CY1110880T1 (el) Αντιγονα neisserial
ATE486887T1 (de) Trägerprotein eines polyepitops
DK1047784T3 (da) Neissera meningitidis-antigener
GB0103424D0 (en) Gonococcus proteins
CY1117235T1 (el) Νεϊσσεριακες συνθεσεις συνδυασμου
PT1154790E (pt) Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
DK1093517T3 (da) Neisseria-meningitidis-antigener og præparater
ATE105189T1 (de) Haemophilus influenzae typ b polysaccharidaussermembranprotein-konjugat als impfstoff.
PT1535928E (pt) Composições de vacina compreendendo proteínas omp85 de neisseria gonorrhoeae e neisseria meningitidis